Dosing Considerations for Bispecific Antibodies in MM

Opinion
Video

Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.

Recent Videos
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Related Content
“[This approval] will be a quite dramatic change in our philosophy and practice in multiple myeloma," according to Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO.

FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma

Russ Conroy
November 6th 2025
Article

Data from the phase 3 AQUILA study support the FDA approval of subcutaneous daratumumab in this smoldering multiple myeloma population.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Investigators are currently assessing the antibody drug conjugate HDP-101 as part of a phase 1/2a study.

HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma

Russ Conroy
October 23rd 2025
Article

Investigators are currently assessing the antibody-drug conjugate HDP-101 as part of a phase 1/2a study.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma

Russ Conroy
October 16th 2025
Article

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma

Roman Fabbricatore
October 13th 2025
Article

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.